Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Nektar Therapeutics stock | $16.12

Learn how to easily invest in Nektar Therapeutics stock.

Nektar Therapeutics is a biotechnology business based in the US. Nektar Therapeutics shares (NKTR) are listed on the NASDAQ and all prices are listed in US Dollars. Nektar Therapeutics employs 718 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Nektar Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NKTR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Nektar Therapeutics stock price (NASDAQ: NKTR)

Use our graph to track the performance of NKTR stocks over time.

Nektar Therapeutics shares at a glance

Information last updated 2021-10-25.
Latest market close$16.12
52-week range$12.92 - $26.75
50-day moving average $17.04
200-day moving average $17.12
Wall St. target price$29.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.63

Buy Nektar Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Nektar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nektar Therapeutics price performance over time

Historical closes compared with the close of $16.12 from 2021-10-25

1 week (2021-10-20) -0.74%
1 month (2021-09-27) -14.44%
3 months (2021-07-27) 1.32%
6 months (2021-04-27) -19.76%
1 year (2020-10-27) -2.18%
2 years (2019-10-25) -3.36%
3 years (2018-10-26) 36.8
5 years (2016-10-27) 31.59%

Is Nektar Therapeutics under- or over-valued?

Valuing Nektar Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nektar Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Nektar Therapeutics's PEG ratio

Nektar Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Nektar Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Nektar Therapeutics financials

Revenue TTM $105.5 million
Gross profit TTM $133.4 million
Return on assets TTM -18.26%
Return on equity TTM -43.89%
Profit margin 0%
Book value $4.92
Market capitalisation $3 billion

TTM: trailing 12 months

Shorting Nektar Therapeutics shares

There are currently 16.2 million Nektar Therapeutics shares held short by investors – that's known as Nektar Therapeutics's "short interest". This figure is 1.7% down from 16.5 million last month.

There are a few different ways that this level of interest in shorting Nektar Therapeutics shares can be evaluated.

Nektar Therapeutics's "short interest ratio" (SIR)

Nektar Therapeutics's "short interest ratio" (SIR) is the quantity of Nektar Therapeutics shares currently shorted divided by the average quantity of Nektar Therapeutics shares traded daily (recently around 895669.35840708). Nektar Therapeutics's SIR currently stands at 18.08. In other words for every 100,000 Nektar Therapeutics shares traded daily on the market, roughly 18080 shares are currently held short.

However Nektar Therapeutics's short interest can also be evaluated against the total number of Nektar Therapeutics shares, or, against the total number of tradable Nektar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nektar Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Nektar Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.1774% of the tradable shares (for every 100,000 tradable Nektar Therapeutics shares, roughly 177 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Nektar Therapeutics.

Find out more about how you can short Nektar Therapeutics stock.

Nektar Therapeutics share dividends

We're not expecting Nektar Therapeutics to pay a dividend over the next 12 months.

Have Nektar Therapeutics's shares ever split?

Nektar Therapeutics's shares were split on a 2:1 basis on 22 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Nektar Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Nektar Therapeutics shares which in turn could have impacted Nektar Therapeutics's share price.

Nektar Therapeutics share price volatility

Over the last 12 months, Nektar Therapeutics's shares have ranged in value from as little as $12.92 up to $26.75. A popular way to gauge a stock's volatility is its "beta".

NKTR.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nektar Therapeutics's is 1.318. This would suggest that Nektar Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Nektar Therapeutics overview

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd. ; AstraZeneca AB; UCB Pharma S. A.

Frequently asked questions

What percentage of Nektar Therapeutics is owned by insiders or institutions?
Currently 0.928% of Nektar Therapeutics shares are held by insiders and 92.466% by institutions.
How many people work for Nektar Therapeutics?
Latest data suggests 718 work at Nektar Therapeutics.
When does the fiscal year end for Nektar Therapeutics?
Nektar Therapeutics's fiscal year ends in December.
Where is Nektar Therapeutics based?
Nektar Therapeutics's address is: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
What is Nektar Therapeutics's ISIN number?
Nektar Therapeutics's international securities identification number is: US6402681083
What is Nektar Therapeutics's CUSIP number?
Nektar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 457191104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site